Guardant Health And Nuvalent Enter Strategic Collaboration For The Development And Potential Commercialization Of Nuvalent's Oncology Pipeline Using The Guardant Infinity Platform's Tissue And Liquid Tools

The collaboration reflects the growing importance of precision diagnostics in oncology drug development, where biomarker-driven approaches are increasingly essential for identifying appropriate patient populations, improving trial efficiency, and supporting regulatory approvals.

As key components of the collaboration, Guardant Health and Nuvalent plan to:

• Utilize Guardant's portfolio of tissue and liquid biopsy tests to support certain Nuvalent global clinical studies;
• Evaluate opportunities to develop Guardant tissue and/or liquid biopsy assays as companion diagnostics (CDx) to support potential regulatory approvals of Nuvalent's current investigational candidates; and,
• Collaborate on the global commercialization of Nuvalent's product candidates, if approved, and Guardant companion diagnostics across major global key markets.